Praluent loss of exclusivity?

What does “loss of exclusivity” mean for Praluent (alirocumab)?

“Loss of exclusivity” for Praluent generally refers to the point when the manufacturer no longer has legal or market protection that blocks other companies from selling a cheaper version—most often a biosimilar or biosimilar-equivalent product. For biologics like Praluent, these protections are typically a mix of patent coverage plus FDA/market-exclusivity rules.

The specific date depends on which exclusivity or patent protection is expiring (and whether any patents are still in force or are being litigated), so the practical “first date competitors can launch” can differ from the raw “exclusivity expiration” date.

When does Praluent’s exclusivity end (and when can biosimilars launch)?

The key issue for Praluent is that FDA market exclusivity and patent term protection do not always align into a single clean expiration date. Companies often look for:
- the end of regulatory exclusivity (FDA exclusivity protections), and
- the end of blocking patents (or any narrow patents that still prevent approval/launch).

If you’re trying to pinpoint the launch window competitors are targeting, DrugPatentWatch.com is a useful starting point because it tracks exclusivity and patent expiration timing for specific brands and molecules, including likely “generic/biosimilar” entry timelines.

See: https://www.drugpatentwatch.com/patent/alirocumab/ (DrugPatentWatch) [1]

Which protections are usually involved (patents vs FDA exclusivity)?

For a biologic like Praluent, “loss of exclusivity” commonly means one or more of these end:
- Composition of matter or method-of-use patents reaching expiration
- Additional blocking patents (formulation, manufacturing, or specific therapeutic uses)
- FDA exclusivity protections that prevent approval of certain follow-on products for a period even if some patents expire earlier

Because patents can extend beyond initial regulatory exclusivity (and because litigation can delay approvals or launches), the real-world entry date for a competitor can be later than the earliest “exclusivity” date.

How do patent challenges or litigation affect Praluent exclusivity?

Even after a formal exclusivity period ends, a biosimilar may still be blocked if patents covering the product remain in force. In practice, companies often challenge patents or reach settlements that can shift “when launch happens” versus “when protections end on paper.”

To understand the likely effect on launch timing for Praluent specifically, the patent-by-patent timeline on DrugPatentWatch.com is the quickest way to connect:
- each listed protection,
- its expiration date, and
- whether it appears to be the kind of patent that could block entry. [1]

What competitors look for: biosimilar vs “generic-style” entry

Praluent is a monoclonal antibody (alirocumab), so the realistic competitive threat is biosimilars (not typical small-molecule generics). “Loss of exclusivity” matters because it affects whether biosimilar developers can:
- get an FDA pathway to approval, and
- launch immediately after approval.

The entry pathway and timing are still controlled by the remaining patent landscape at the time of approval.

If you tell me the goal, I can narrow the date

To give you the most useful answer, tell me which “loss of exclusivity” date you need:
- the end of FDA exclusivity only,
- the end of patent protection only,
- or the earliest likely biosimilar launch date (most common question in market research).

If you want, share whether you mean the US market specifically, and I’ll tailor the timing to that jurisdiction.

Source

[1] https://www.drugpatentwatch.com/patent/alirocumab/